Emergent Biosolutions Inc. · NYSE:EBS
Emergent Biosolutions — 37th Annual J.P. Morgan Healthcare Conference 2019
20 slides from Emergent Biosolutions's conference presentation, Jan 7, 2019
Slide 1: Corporate Update - 37th Annual J.P. Morgan Healthcare Conference
37th Annual J.P. MorganHealthcare Conference January 8, 2019 Robert KramerPresident and COO Corporate Update
Slide 2: Forward-Looking Statements / Non-GAAP Financial Measures / Trademarks
Forward-Looking Statements / Non-GAAP Financial Measures / Trademarks Safe-Harbor StatementThis presentation includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements, other than statements of historical fact, including, without li
Slide 3: Who We Are
As a global life sciences company, Emergent is focused on providing specialty products for civilian and military populations that address accidental, deliberate and naturally occurring public health threats Who We Are Our mission is simple – To Protect and Enhance Life
Slide 4: Who We Are: Key Facts
MultipleCDMO Services 19Global Locations >15PipelineProducts 11MarketedProducts 4PlatformTechnologies
Slide 5: Track Record of Profitable, Diversified Growth
Track Record of Profitable, Diversified Growth Revenue Diversification 2012 2018E Other Product Sales Contract Manufacturing Contracts and Grants 78% 22% Growth in Profitability $278M ($ 000’s) ($ Millions) Revenue Growth Who We Are Adj. Net Income1 Adj. EBITDA1 $782M 41% 10% 13% 2018E financial res
Slide 6: A Diverse and Growing Global Threat Landscape
A Diverse and Growing Global Threat Landscape Global Public Health Threats1 CBRNE EID Travelers’Diseases Opioids Public CHEMICAL:Nerve agents, cyanide, chlorine, toxic industrial chemicalsBIOLOGICAL:Anthrax, smallpox, botulism, Ebola, other category A threats RADIOLOGICAL/NUCLEAR:Nuclear, radiologic
Slide 7: Business Unit Structure Drives Strategy Execution
Business Unit Structure Drives Strategy Execution Focused leadership teamsTailored strategies and plansRevenue-generating products/servicesUnique development programsDistinctive core competenciesStreamlined operations Our Business Vaccines & Anti-Infectives Antibody Therapeutics Devices CDMO
Slide 8: Product Portfolio: Vaccines, Antibody Therapeutics, Drug-Device Combinations
BioThrax® (Anthrax Vaccine Adsorbed) Anthrasil® [Anthrax Immune Globulin Intravenous (human)] Raxibacumab injectionA fully human monoclonal antibody Product Portfolio | Vaccines, Antibody Therapeutics, Drug-Device Combinations Our Business VIGIV CNJ-016 ® [Vaccinia Immune Globulin Intravenous (Human
Slide 9: Development Pipeline: Vaccines, Anti-Infectives, Antibody Therapeutics
Our Business Development Pipeline | Vaccines, Anti-Infectives, Antibody Therapeutics Development Candidate Threat Partner Priority Review Voucher1 Pre Clinical Clinical Phase I II III NuThrax™ AV7909(anthrax vaccine adsorbed with CPG 7909 adjuvant) CBRNE HHS - BARDA - 20192 FLU-IGIV(Seasonal Influen
Slide 10: Development Pipeline: Drug-Device Combinations
Development Pipeline | Drug-Device Combinations Our Business Development Candidate Threat Partner Priority Review Voucher1 Formative Studies RegistrationTrials Regulatory Application D4(2PAM/Atropine) CBRNE DoD - MCS - SIAN(Stabilized Isoamyl Nitrite) CBRNE HHS - BARDA/SwRI - Development Candidates
Slide 11: Robust and Growing CDMO Service Business
Robust and Growing CDMO Service Business Experienced Service Provider Producing or supporting manufacture of >30 commercial productsContributed to development, production of >200 clinical products Inspected by: Our Business Lansing, MI Hattiesburg, MS Baltimore, MD (Bayview) - CIADM Baltimore, MD (C
Slide 12: 2018 Performance: Financial Profile
2018 Performance Financial Profile 1 2018 preliminary unaudited financial results shown in this presentation are only effective as of January 7, 2018, the date it was originally provided. Please see the appendix for non-GAAP reconciliation tables.2 See the Appendix for non-GAAP reconciliation tables
Slide 13: 2019 Financial and Operational Goals
2019 Financial and Operational Goals Financial Profile Full Year Financial Goals1 Total Revenue Adjusted Net Income2Margin3 $150M-$180M15% $1,060M-$1,140M Operational Goals Secure EUA approval for NuThrax™ and complete deliveries under existing BARDA contractSecure new multi-year ACAM2000® and raxib
Slide 14: Growth Drivers: Organic Business
Growth Drivers | Organic Business Future Plans Platform technologiesInternational marketsDual-market productsPriority Review Vouchers New Contracts and Grants funding (USG, NGO)Novel regulatory pathways (EUA, fast track and breakthrough)Expanded manufacturing technology and service offerings Near-Te
Slide 15: Growth Drivers: Mergers & Acquisitions
Adapt PharmaFirst and only FDA approved nasal (non-needle) form of naloxone for opioid overdose (drug/device combination), development pipeline Growth Drivers | Mergers & Acquisitions Future Plans Revenue-generating/accretive opportunitiesDual-market productsCommercial products that leverage core ca
Slide 16: Key Takeaways
Key Takeaways Expand leadership position in select public health marketsLeverage broadened product portfolio and extend into new and adjacent marketsCapture dual-market and commercial product opportunitiesFurther develop pipelineComplement organic growth with acquisitionsDrive material top- and bott
Slide 17: Appendix
37th Annual J.P. MorganHealthcare Conference January 8, 2019 Robert KramerPresident and COO APPENDIX
Slide 18: Glossary of Terms
Glossary of Terms Appendix Term Definition ANVISA National Health Surveillance Agency Brazil BARDA Biomedical Advanced Research and Development Authority BMGS Federal Ministry of Health Germany BSL3 A biosafety level of biocontainment precautions required to isolate dangerous agents in an enclosed l
Slide 19: Glossary of Terms
Glossary of Terms Appendix Term Definition EMA European Medicines Agency EUA Emergency Use Authorization FDA U.S. Food and Drug Administration GAAP U.S. Generally Accepted Accounting Principles HHS U.S. Department of Health and Human Services M&A Mergers and acquisitions MCS Medical Countermeasure S
Slide 20: Reconciliation Tables
Reconciliation Tables Appendix Reconciliation of Net Income to Adjusted Net Income Reconciliation of Net Income to EBITDA & Adjusted EBITDA Unaudited Unaudited
Emergent BioSolutions — 37th Annual J.P. Morgan Healthcare Conference 2019 on 6ix